Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody

被引：7

作者：

Seth, Abhishek ^{[1
]}

Murray, David ^{[2
]}

Buadi, Francis K. ^{[1
]}

Gertz, Morie A. ^{[1
]}

Yadav, Udit ^{[1
]}

Kumar, Shaji K. ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

机构：

[1] Mayo Clin, Dept Hematol, 200 First St SW, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 111卷 / 02期

基金：

美国国家卫生研究院;

关键词：

daratumumab; impaired mobilization; mass-spectrometry; multiple myeloma; MULTIPLE-MYELOMA;

D O I：

10.1111/ejh.14008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Daratumumab is an anti-CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher-than-expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.

引用

页码：318 / 321

页数：4

共 50 条

[21] Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
Zamanillo, Irene
De la Puerta, Rosalia
Gil, Rodrigo
Poza, Maria
De la Puerta, Rodrigo
Alonso, Rafael
Cedena, Teresa
Calbacho, Maria
Ayala, Rosa
Martinez-Lopez, Joaquin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S164 - S165
[22] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
Pimentel, Villar M. A.
Anguita, Arance M. M.
Almagro, Torres F.
Lopez, Lopez J. A.
HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
[23] Case Study: Interference With Compatibility Testing Caused by Anti-CD38 Humanized Monoclonal Antibody (Isatuximab)
Perzan, Stacy
Gresens, Christopher J.
Almaz, Bassam
Doane, Rebecca
Veneman, Susan
TRANSFUSION, 2019, 59 : 135A - 136A
[24] A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing
Chinoca Ziza, Karen N.
Paiva, Taina A.
Mota, Sabrina R.
Dezan, Marcia Regina
Schmidt, Luciana Cayres
Brunetta, Denise Menezes
Ricci, Gustavo
Basques, Fernando Valadares
Barroso-Duarte, Fernando
Rocha, Vanderson
Mendrone-Junior, Alfredo
Dinardo, Carla Luana
TRANSFUSION, 2019, 59 (05) : 1827 - 1835
[25] Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.
Nijhof, Inger S.
Lokhorst, Henk M.
van Kessel, Berris
Doshi, Parul
Sasser, Kate
Mutis, Tuna
van de Donk, Niels W. C. J.
CLINICAL CANCER RESEARCH, 2015, 21
[26] Impact of monoclonal anti-CD38 antibody on collected myeloid and erythroid progenitor cells and clinical course of autologous stem cell transplant for patients with multiple myeloma
Manjappa, Shivaprasad
Eduafo, Augusta
Fox, Robert
Reese, Jane
Schmikla, Hannah
Kolk, Merle
Driscoll, James
Malek, Ehsan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S50 - S50
[27] Development of an anti-porcine CD34 monoclonal antibody that identifies hematopoietic stem cells
Layton, Daniel S.
Strom, A. David G.
O'Neil, Terri E.
Broadway, Mary M.
Stephenson, Garth L.
Morris, Kirsten R.
Muralitharan, Morley
Sandrin, Mauro S.
Ierino, Francesco L.
Bean, Andrew G. D.
EXPERIMENTAL HEMATOLOGY, 2007, 35 (01) : 171 - 178
[28] ANTI-CD38 TREATMENT AS A PREDICTIVE FACTOR FOR STEM CELL MOBILIZATION FAILURE AND DELAYED GRAFT RECOVERY IN MULTIPLE MYELOMA: A TERTIARY HOSPITAL EXPERIENCE
Zoco Gallardo, Paula
Garcia Ascacibar, Ariadna
Mateos Mazon, Juan
Posada Alcon, Laura
Arzuaga Mendez, Javier
Arrieta Aguilar, Julia
Uresandi Iruin, Amaia
Balerdi Malcorra, Amaia
Amutio Diez, Maria Elena
Casado Sanchez, Maria
Hormaza De Jauregui, Sara
Pinedo Martin, Gorka
Aranguren Del Castillo, Laura
Lobo Olmedo, Ana
Amutio Diez, Maria Elena
Garcia Ruiz, Juan Carlos
BONE MARROW TRANSPLANTATION, 2024, 59 : 651 - 652
[29] Solid phase antibody screening in the presence of anti-CD38 monoclonal antibodies: a potential alternative to avoid interference
Perram, J.
Blayney, B.
Ackerman, L.
Beig, A.
Khoo, L.
PATHOLOGY, 2020, 52 (04) : 492 - 494
[30] Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
Lonial, Sagar
Bowser, Andrew D.
Chari, Ajai
Costello, Caitlin
Krishnan, Amrita
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 815 - 824

← 1 2 3 4 5 →